Latest news
VivoSense Announces Closing of $25M Series A Financing Round Co-led by Xontogeny and Debiopharm
Challenge pour la Qualité de vie du patient 2022 : l’appel à projets est ouvert !
Debiopharm and Aspen Partner to Launch Prostate Cancer Drug Trelstar® in South Africa
Debiopharm invests in VeriSIM Life’s $15m series A round to advance AI-enabled drug research
Debiopharm further explores the potential of its potent, highly selective WEE1 inhibitor Debio 0123 in phase 1 cancer study
Grand gagnant du 6eme Challenge 2021 pour la qualité de vie du patient, le projet WheelyWasher permet de nettoyer automatiquement…
Swiss-based Debiopharm co-invests in the future of cell therapies on a chip through the latest $25 million Series A round…
CARB-X Funds The 3rd Round of Debiopharm’s Targeted Antibiotic Program To Combat Resistant N. Gonorrhoeae Infections
Debiopharm & Dexa Medica Launch Triptorelin Collaboration to Bring New Hope To Women With Endometriosis
Stay informed
Don't miss any latest news and announcements on Debiopharm Investment, subscribe to our newsletter.